Ipsen, a biopharmaceutical company focused on medicines in oncology, rare diseases and neuroscience, have been denied marketing authorisation by the Committee for Medicinal Products for Human Use (CHMP) of the EMA for their drug palovarotene.
Ipsen reports CHMP negative review for use of palovarotene in EU
